Outcomes of patients with localized prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy boost: A single-center retrospective study
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Bergengren O, Pekala KR, Matsoukas K et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol 2023; 84: 191–206.BergengrenOPekalaKRMatsoukasK2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic ReviewEur Urol202384191206Search in Google Scholar
Mendez LC, Morton GC. High dose-rate brachytherapy in the treatment of prostate cancer. Transl Androl Urol 2018; 7: 357–70.MendezLCMortonGCHigh dose-rate brachytherapy in the treatment of prostate cancerTransl Androl Urol2018735770Search in Google Scholar
Georg D, Hopfgartner J, Gòra J et al. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2014; 88: 715–22.GeorgDHopfgartnerJGòraJDosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapyInt J Radiat Oncol Biol Phys20148871522Search in Google Scholar
Spratt DE, Scala LM, Folkert M et al. A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. Brachytherapy 2013; 12: 428–33.SprattDEScalaLMFolkertMA comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancerBrachytherapy20131242833Search in Google Scholar
Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095–101.BrennerDJHallEJFractionation and protraction for radiotherapy of prostate carcinomaInt J Radiat Oncol Biol Phys1999431095101Search in Google Scholar
Brenner DJ, Martinez AA, Edmundson GK et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52: 6–13.BrennerDJMartinezAAEdmundsonGKDirect evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissueInt J Radiat Oncol Biol Phys200252613Search in Google Scholar
Vogelius IR, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 2013; 85: 89–94.VogeliusIRBentzenSMMeta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?Int J Radiat Oncol Biol Phys2013858994Search in Google Scholar
Martinez AA, Gonzalez J, Ye H, et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 363–370.MartinezAAGonzalezJYeHDose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapyInt J Radiat Oncol Biol Phys201179363370Search in Google Scholar
Kishan AU, Cook RR, Ciezki JP et al. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9–10 Prostate Cancer. Jama 2018; 319: 896–905.KishanAUCookRRCiezkiJPRadical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9–10 Prostate CancerJama2018319896905Search in Google Scholar
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2023https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.Search in Google Scholar
D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 1998; 280: 969–74.D’AmicoAVWhittingtonRMalkowiczSBBiochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancerJama199828096974Search in Google Scholar
Harris VA, Staffurth J, Naismith O et al. Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 2015; 92: 874–83.HarrisVAStaffurthJNaismithOConsensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation TherapyInt J Radiat Oncol Biol Phys20159287483Search in Google Scholar
Morton G, Loblaw A, Cheung P et al. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol 2011; 100: 463–7.MortonGLoblawACheungPIs single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?Radiother Oncol20111004637Search in Google Scholar
Hoskin PJ, Colombo A, Henry A et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 2013; 107: 325–32.HoskinPJColomboAHenryAGEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an updateRadiother Oncol201310732532Search in Google Scholar
Roach M, 3rd, Hanks G, Thames H et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965–74.RoachM3rdHanksGThamesHDefining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInt J Radiat Oncol Biol Phys20066596574Search in Google Scholar